EUVIMEDEUVIMED entdecken
Fallbericht

Cetuximab-Induced Acneiform Eruption: A Case Report

Büşra GÜNER, Türkkan EVRENSEL, Sibel OYUCU ORHAN

Turkish Journal of Internal Medicine · 2022

DOI: 10.46310/tjim.1071185 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Turkish Journal of Internal Medicine, 2022. Verfasst von Büşra GÜNER und 2 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor (EGFR) monoclonal antibody inhibitors are used to treat metastatic colorectal cancers. Cetuximab, an EGFR inhibitor drug, targets specific molecular pathways and does not cause the severe systemic side effects seen in cytotoxic chemotherapy. Herein, we presented a case who developed acneiform eruptions during cetuximab treatment.

Zitieren

APA

GÜNER, B., EVRENSEL, T., & ORHAN, S. O. (2022). Cetuximab-Induced Acneiform Eruption: A Case Report. Turkish Journal of Internal Medicine. https://doi.org/10.46310/tjim.1071185

Vancouver

GÜNER B, EVRENSEL T, ORHAN SO. Cetuximab-Induced Acneiform Eruption: A Case Report. Turkish Journal of Internal Medicine. 2022. doi:10.46310/tjim.1071185

BibTeX
@article{GNER2022,
  author = {GÜNER, Büşra and EVRENSEL, Türkkan and ORHAN, Sibel OYUCU},
  title = {Cetuximab-Induced Acneiform Eruption: A Case Report},
  journal = {Turkish Journal of Internal Medicine},
  year = {2022},
  doi = {10.46310/tjim.1071185}
}
Kostenlos starten →